By Josh Beckerman
Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results.
The stock was recently down 10% to $6.20 and is down about 2% this year.
Revenue declined to $7.93 million from $9.74 million. Analysts surveyed by FactSet, on average, expected $7.9 million. Loss was 6 cents a share, compared with analysts' estimates for a loss of 13 cents a share.
In September 2022, the Food and Drug Administration approved Fennec's Pedmark, a sodium thiosulfate formulation, to reduce the risk of ototoxicity associated with cisplatin in certain pediatric patients with tumors.
Fennec said Monday that it is seeing encouraging momentum in early 2025, particularly with adoption by academic institutions and new patient segments. A Pedmark clinical trial in Japan fully enrolled in the fourth quarter and results are expected in the second half of 2025.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
March 10, 2025 15:37 ET (19:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.